Guidelines for Therapy for Atopic Dermatitis 2003

  • Furue Masutaka
    Department of Dermatology, Fuculty of Medical Sciences, Kyushu University
  • Furukawa Fukumi
    Department of Dermatology, Wakayama Medical University
  • Hide Michihiro
    Department of Dermatology, Hiroshima Universiry Graduate School of Biomedical Sciences
  • Takehara Kazuhiko
    Aniogenesis and Connective Tissue Metabolism, Kanazawa University Graduate School of Medicine

Bibliographic Information

Other Title
  • 全文訂正版:日本皮膚科学会アトピー性皮膚炎治療ガイドライン2003改訂版
  • 生涯教育講座 日本皮膚科学会アトピー性皮膚炎治療ガイドライン2003改訂版
  • ショウガイ キョウイク コウザ ニホン ヒフ カガクカイ アトピーセイ ヒフエン チリョウ ガイドライン 2003 カイテイバン
  • 全文改訂版 日本皮膚科学会アトピー性皮膚炎治療ガイドライン2003改訂版
  • ゼンブン カイテイバン ニホン ヒフ カガクカイ アトピーセイ ヒフエン チリョウ ガイドライン 2003 カイテイバン

Search this article

Abstract

Recently in Japan, misunderstandings about the pathogenesis of atopic dermatitis (AD) and the strategies for the treatment of this disease, especially about the use of topical steroid, have led to a rapid increase of severe cases of AD caused by inadequate treatment. This prompted us to establish and distribute standard guidelines for AD therapy. In this guideline, the necessity of dermatological training to examine severe cases of AD is emphasized. It is stated that the present standard therapies for AD consist of the use of topical steroid and tacrolimus ointment (only for adult patients) for inflammation and emollient for dry and barrier—disrupted skin as the first line of attack, anti-histamines and anti-allergic drugs for pruritus, avoidance of apparent exacerbating factors, psychological counselling, and advice about daily life. The importance of correct selection of topical steroid according to the severity of the lesion is emphasized.

Journal

Citations (17)*help

See more

Details

Report a problem

Back to top